AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa Nippon Shinyaku…
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
BALTIMORE, June 26, 2026 (GLOBE NEWSWIRE) — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for rare…
Japan Accelerates Development of ASSBs and Supply Chain Buildout, with Government Subsidies Reaching $660 Million, Says TrendForce
TrendForce Corp. TAIPEI, Taiwan, June 25, 2026 (GLOBE NEWSWIRE) — TrendForce’s latest “2Q26 Global Solid-State Battery Industry Development…
Quoin completes Japan subsidiary for QRX003
Quoin Pharmaceuticals (NASDAQ: QNRX) has completed establishing a wholly-owned subsidiary in Japan to…
SkyDrive Becomes Japan’s First eVTOL Developer to Earn “Approved Design Organization” (ADO) Certification
April 17, 2026: SkyDrive received the ADO certification at the Aircraft Engineering and Certification Center (AECC). From left:…